Grail tanks after cancer detection test fails in key study
Hims & Hers announced a partnership with the company earlier this month.
A blood test for detecting cancer early that was indirectly advertised at the Super Bowl failed in a major study.
Grail, the diagnostics company developing the test, Galleri, announced top-line results of a major trial with England's National Health Service, which did not show a statistically significant reduction in later-stage cancers among people who took the test, though there was “a favorable trend over time.” Grail sold 185,000 Galleri tests in 2025, generating $136.8 million, up from $109 million in 2024.
The company is down more than 50% in premarket trading.
The test, which has a list price of $949, has been available through consumer health platforms like Function Health, a lab analysis startup, which announced in December that it would offer Galleri tests.
Hims & Hers announced earlier this month that it would offer Galleri tests on its lab analysis product.
The company teased the new partnership in its Super Bowl ad, touting “early cancer detection through a simple blood test.” The ad showed a man breathing a sigh of relief after seeing his phone screen confirm, “No cancer signal detected.”
